Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of huntington disease

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Kolodziejczyk, Karolina ^a   Parsons, Matthew P ^a   Southwell, Amber L ^b   Hayden, Michael R ^b   Raymond, Lynn A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; N METHYLASPARTIC ACID;

ACTION POTENTIAL; AGE; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAG REPEAT; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; HETEROZYGOSITY; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; HU97 18 MOUSE; HUNTINGTON CHOREA; LONG TERM POTENTIATION; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE CELL; NERVE CELL MEMBRANE CONDUCTANCE; NERVE CELL PLASTICITY; NONHUMAN; SPINY PROJECTION NEURON; SPONTANEOUS EXCITATORY POSTSYNAPTIC CURRENT; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE; ANIMAL; CELL MEMBRANE; DISEASE MODEL; HUMAN; METABOLISM; NEOSTRIATUM; PATHOLOGY; PATHOPHYSIOLOGY; PYRAMIDAL NERVE CELL; SYNAPSE;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; CA1 REGION, HIPPOCAMPAL; CELL MEMBRANE; DISEASE MODELS, ANIMAL; EXCITATORY POSTSYNAPTIC POTENTIALS; HIPPOCAMPUS; HUMANS; HUNTINGTON DISEASE; LONG-TERM POTENTIATION; MICE; MICE, TRANSGENIC; N-METHYLASPARTATE; NEOSTRIATUM; NEURONAL PLASTICITY; NEURONS; PYRAMIDAL CELLS; SYNAPSES;

EID: 84899658012     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094562     Document Type: Article

References (40)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983.
2. Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90: 905-981.
3. Di Filippo M, Tozzi A, Picconi B, Ghiglieri V, Calabresi P (2007) Plastic abnormalities in experimental Huntington's disease. Curr Opin Pharmacol 7: 106-111.
4. Raymond LA, André VM, Cepeda C, Gladding CM, Milnerwood AJ, et al. (2011) Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 198: 252-273.
5. Ghiglieri V, Bagetta V, Calabresi P, Picconi B (2012) Functional interactions within striatal microcircuit in animal models of Huntington's disease. Neuroscience 211: 165-184.
6. Southwell AL, Skotte NH, Bennett CF, Hayden MR (2012) Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol Med 18: 634-643.
7. Martinez T, Wright N, López-Fraga M, Jiménez AI, Pañeda C (2013) Silencing human genetic diseases with oligonucleotide- based therapies. Hum Genet 132: 481-493.
8. Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, et al. (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol Ther 19: 2178-2185.
9. Cepeda C, Cummings DM, André VM, Holley SM, Levine MS (2010) Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro 2: e00033.
10. Pouladi MA, Morton AJ, Hayden MR (2013) Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci 14: 708-721.
11. Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, et al. (2013) A fully humanized transgenic mouse model of Huntington disease. Hum Mol Genet 22: 18-34.
12. Milnerwood AJ, Raymond LA (2007) Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load. J Physiol 585: 817-831.
13. Kiraly DD, Lemtiri-Chlieh F, Levine ES, Mains RE, Eipper BA (2011) Kalirin binds the NR2B subunit of the NMDA receptor, altering its synaptic localization and function. J Neurosci 31: 12554-12565.
14. Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, et al. (2009) Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J Neurosci 29: 2193-2204.
15. Singaraja RR, Huang K, Sanders SS, Milnerwood AJ, Hines R, et al. (2011) Altered palmitoylation and neuropathological deficits in mice lacking HIP14. Hum Mol Genet 20: 3899-3909.
16. Thomson AM (2000) Facilitation, augmentation and potentiation at central synapses. Trends Neurosci 23: 305-312.
17. Cepeda C, Hurst RS, Calvert CR, Hernández-Echeagaray E, Nguyen OK, et al. (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23: 961-969.
18. Joshi PR, Wu NP, André VM, Cummings DM, Cepeda C, et al. (2009) Agedependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J Neurosci 29: 2414-2427.
19. Cepeda C, Ariano MA, Calvert CR, Flores-Hernández J, Chandler SH, et al. (2001) NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66: 525-539.
20. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, et al. (2010) Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65: 178-190.
21. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, et al. (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23: 181-192.
22. Usdin MT, Shelbourne PF, Myers RM, Madison DV (1999) Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum Mol Genet 8: 839-846.
23. Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, et al. (2000) Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20: 5115-5123.
24. Lynch G, Kramar EA, Rex CS, Jia Y, Chappas D, et al. (2007) Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J Neurosci 27: 4424-4434.
25. Cummings DM, Cepeda C, Levine MS (2010) Alterations in striatal synaptic transmission are consistent across genetic mouse models of Huntington's disease. ASN Neuro 2: e00036.
26. Ariano MA, Cepeda C, Calvert CR, Flores-Hernández J, Hernández-Echeagaray E, et al. (2005) Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J Neurophysiol 93: 2565-2574.
27. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, et al. (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58: 515-532.
28. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, et al. (2001) Electrophysiological and morphological changes in striatal spiny neurons in R6/ 2 Huntington's disease transgenic mice. J Neurophysiol 86: 2667-2677.
29. Rebec GV, Conroy SK, Barton SJ (2006) Hyperactive striatal neurons in symptomatic Huntington R6/2 mice: variations with behavioral state and repeated ascorbate treatment. Neuroscience 137: 327-336.
30. Gray M, Shirasaki DI, Cepeda C, André VM, Wilburn B, et al. (2008) Fulllength human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28: 6182-6195.
31. Cummings DM, André VM, Uzgil BO, Gee SM, Fisher YE, et al. (2009) Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci 29: 10371-10386.
32. Li L, Murphy TH, Hayden MR, Raymond LA (2004) Enhanced striatal NR2Bcontaining N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. J Neurophysiol 92: 2738-2746.
33. Cowan C, Fan MM, Fan J, Shehadeh J, Zhang LY, et al. (2008) Polyglutaminemodulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity. J Neurosci 28: 12725-12735.
34. Gladding CM, Sepers MD, Xu J, Zhang LY, Milnerwood AJ, et al. (2012) Calpain and STriatal-Enriched protein tyrosine phosphatase (STEP) activation contribute to extrasynaptic NMDA receptor localization in a Huntington's disease mouse model. Hum Mol Genet 21: 3739-3752.
35. Simmons DA, Rex CS, Palmer L, Pandyarajan V, Fedulov V, et al. (2009) Upregulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc Natl Acad Sci USA 106: 4906-4911.
36. Minichiello L (2009) TrkB signalling pathways in LTP and learning. Nat Rev Neurosci 10: 850-860.
37. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293: 493-498.
38. Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, et al. (2009) Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15: 1407-1413.
39. Cummings DM, Alaghband Y, Hickey MA, Joshi PR, Hong SC, et al. (2012) A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease. J Neurophysiol 107: 677-691.
40. Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, et al. (2012) Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum Mol Genet 21: 2219-2232.